Aura Biosciences, Inc.

NASDAQ: AURA · Healthcare · Biotechnology

PublicHQ Boston, MA · SuffolkCIK 0001501796Reports USD

#1 of 1,422 Healthcare companies by revenue

EA Score

——

FH 47DQ —GM —SS 53

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, market scale · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$106.2M

Employees

113

as of 2026-08-12

Market cap

$831.6M

as of 2026-08-12

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$106.2M-$106.2M2025

Operating income-$112.8M-$112.8M2025

Total assets$169.4M$169.4M2025

Liabilities$32.5M$32.5M2025

Equity$136.9M$136.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is Aura Biosciences, Inc.’s financial profile?

Aura Biosciences, Inc. earned -$106.2M in FY2025 net income.

Peers · Healthcare

Sana Biotechnology, Inc.——Annexon, Inc.——Faeth Therapeutics, Inc.——Climb Bio, Inc.——Bright Minds Biosciences Inc.——SpyGlass Pharma, Inc. Common Stock——

Neighbors

Suffolk →

Vertex Pharmaceuticals Incorporated$12.0B88A American Tower Corporation$935.9M76B+State Street Corporation$13.9B67B NSTAR Electric Company——Toast, Inc.$6.2B66B PTC Inc.$2.7B83B+

Key facts

CEONatalie C. Holles

SectorHealthcare

IndustryBiotechnology

HeadquartersBoston, MA

ExchangeNASDAQ: AURA

Employees113

IPO date2021-10-29

Latest filings

8-K2026-08-11 10-Q2026-08-11 8-K2026-08-05 8-K2026-07-08 DEF 14A2026-06-29 8-K2026-06-11 10-Q2026-05-11 8-K2026-05-11

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.